| Literature DB >> 30938532 |
Alexander Wimmer1, Burkhard König1.
Abstract
The pharmaceutically underexplored sulfoximine moiety has emerged as a potentially active pharmaceutical ingredient. We developed a scalable synthetic route to N-arylated sulfoximines from the respective "free" NH-sulfoximines and bromoarenes. Our strategy is based on a dual nickel photocatalytic approach, is applicable for a broad scope of substrates, and exhibits a highly functional group tolerance. In addition, we could demonstrate that other sulfoximidoyl derivatives like sulfonimidamides and sulfinamides proceed smoothly under the developed reaction conditions.Entities:
Year: 2019 PMID: 30938532 PMCID: PMC6480096 DOI: 10.1021/acs.orglett.9b00698
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005
Figure 1(A) Classic transition-metal-catalyzed N-arylations of NH-sulfoximines. (B) Dual nickel photocatalyzed approach.
Optimization of the Reaction Conditionsa,b
| entry | [Ir]-Cat(mol %) | [Ni]-Cat (mol %) | TMG (equiv) | yield | |
|---|---|---|---|---|---|
| 1 | 1.5:1.0 | 1.0 | 1.5 | 94 | |
| 2 | 1.5:1.0 | 0.15 | 1.5 | 96 | |
| 3 | 1.5:1.0 | 0.15 | 1.5 | 95 | |
| 4 | 1.5:1.0 | 0.15 | 1.5 | 76 | |
| 5 | 1.0:1.1 | 0.15 | 1.5 | 99 | |
| 6 | 1.0:1.1 | 0.15 | 1.2 | 99 | |
| 7 | 1.0:1.1 | 0.15 | 1.2 | 99 |
[Ir]-Cat = [Ir(ppy)2(dtbbpy)]PF6, [Ni-1]-Cat = NiBr2 + dtbbpy (1.0:0.20 equiv) added separately, [Ni-2]-Cat = preformed [Ni(dtbbpy]Br2, TMG = 1,1,3,3-tetramethylguanidine,
Reaction conditions: 1a (0.25 mmol, 1.0 equiv), 2a (0.28 mmol, 1.1 equiv), [Ir]-Cat (0.15 mol %), [Ni-2]-Cat (0.20 mol %), TMG (0.30 mmol, 1.2 equiv), dry and degassed DMSO (0.25 M, 1.0 mL), irradiation at 455 nm for 3 h.
Yields were determined by GC analysis with naphthalene as internal standard.
Reaction was up-concentrated to 0.75 M and run for 17 h, and the yield is reported after purification via automated flash-column chromatography.
Figure 2Substrate scope of bromoarenes. Reaction conditions: 1a (0.25 mmol, 1.0 equiv), bromo arene (2) (0.275 mmol, 1.1 equiv), [Ir]-Cat (0.15 mol %), [Ni-2]-Cat (0.20 mol %), TMG (1.2 equiv), dry and degassed MeCN (•) or DMA (#) (0.25 M), irradiation at 455 nm for 17 h; (a) 3.5 h; 17 h for the large-scale reaction; (b) 0.5 mol % of [Ir]-Cat, 1.0 mol % of [Ni-2]-Cat; (c) 0.2 mol % of [Ir]-Cat, 1.0 mol % of [Ni-2]-Cat; (d) 1,3-dibromobenzene (0.24 mmol, 1 equiv) as limiting reagent; (e) 0.5 mol % of [Ni-2]-Cat; (f) 0.5 mol % of [Ir]-Cat, 5.0 mol % of [Ni-2]-Cat; (g) 1.0 mol % of [Ir]-Cat, 5.0 mol % of [Ni-2]-Cat; (h) 1.0 mol % of [Ni-2]-Cat; (i) 0.5 mol % of [Ir]-Cat, 3.0 mol % of [Ni-2]-Cat; (j) 0.5 mol % of [Ir]-Cat, 2.0 mol % of [Ni-2]-Cat; (k) 2.0 mol % of [Ni-2]-Cat; (l) 0.15 mol % of [Ir]-Cat, 2.0 mol % of [Ni-2]-Cat, 0.04 M.
Figure 3(A) Scope of NH-sulfoximines. (B) Scope of enantiopure substrates. (C) Scope of other sulfoximidoyl derivatives. Reaction conditions: NH-sulfoximine (1) (0.25 mmol, 1.0 equiv), methyl 4-bromobenzoate (2j) (0.275 mmol, 1.1 equiv), [Ir]-Cat (0.15 mol %), [Ni-2]-Cat (0.20 mol %), TMG (1.2 equiv), dry and degassed MeCN (•) or DMA (#) (0.25 M), irradiation at 455 nm for 17 h; (a) 0.5 mol % of [Ir]-Cat, 1.0 mol % of [Ni-2]-Cat; (b) 0.5 mol % of [Ir]-Cat, 5.0 mol % of [Ni-2]-Cat; (c) 1.0 mol % of [Ir]-Cat, 5.0 mol % of [Ni-2]-Cat; (d) 0.5 mol % of [Ir]-Cat, 2.0 mol % of [Ni-2]-Cat.